{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-021353","form_type":"8-K","ticker":"LTRN","cik":"0001763950","company_name":"Lantern Pharma Inc.","filed_at":"2024-05-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.962381+00:00","generated_at":"2026-06-01T08:47:10.882925+00:00","sec_items":["5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Lantern Pharma amends bylaws to streamline director count setting","bullets":["Board of Directors approved amendment to Section 3.02 of Bylaws on May 23, 2024, effective immediately.","Previous language required a majority of total directors (including vacancies) to set board size; now any board resolution suffices.","Authorized board size remains unchanged at minimum 3 and maximum 9 directors."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-021353","json":"https://secwatch.observer/filing/0001493152-24-021353.json","markdown":"https://secwatch.observer/filing/0001493152-24-021353.md","text":"https://secwatch.observer/filing/0001493152-24-021353.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1763950/000149315224021353/0001493152-24-021353-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1763950/000149315224021353/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T08:47:10.882925+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}